Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Lorenz TrümperGerman High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Abstract

To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support. Randomized phase I/II multicenter four-level (cyclophosphamide: 1000-1200-1400-1600 mg/m2; doxorubicin: 55-60-65-70 mg/m2; etoposide: 375-450-525-600 mg/m2) dose escalation study with CHOEP-14 and CHOEP-21 in young patients (18-60 years) with newly diagnosed aggressive non-Hodgkin's lymphoma. Dose-limiting toxicity was defined as thrombocytopenia <80,000/mm3 and leukocytopenia <2500/mm3 on days 16 (CHOEP-14) and 23 (CHOEP-21) or prolonged (>4 days) leukocytopenia (<1000/mm3) or thrombocytopenia (<20,000/mm3). One hundred and thirty-nine patients (high-CHOEP-14: 47, high-CHOEP-21: 92) were randomly allocated to the study. Maximal tolerated dose was level 2 for CHOEP-14 and level 4 for CHOEP-21. With a less favorable profile of patients in CHOEP-14, 4-year event-free survival was 47.9% after high-CHOEP-14 and 66.2% after high-CHOEP-21, 4-year overall survival 62.1% after high-CHOEP-14 and 73.4% after high-CHOEP-21, respectively. Significant dose escalations of CHOEP are possible with granulocyte colony-stimulating factor su...Continue Reading

References

Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerM D Goodyear
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A ShippL N Shulman
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H TillyB Coiffier

❮ Previous
Next ❯

Citations

Mar 2, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Matti AaproDidier Kamioner
Jun 3, 2014·Theoretical Biology & Medical Modelling·Sibylle SchirmMarkus Scholz
Dec 30, 2014·BMC Systems Biology·Sibylle SchirmMarkus Scholz
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhard HeldMichael Pfreundschuh
Feb 7, 2017·Journal of Biopharmaceutical Statistics·Cody ChiuzanShing M Lee
Nov 6, 2017·Journal of Cancer Research and Clinical Oncology·Sibylle SchirmMarkus Scholz
Oct 16, 2016·International Journal of Clinical Oncology·Helen Ma, Maher Abdul-Hay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Michael PfreundschuhGerman High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
© 2021 Meta ULC. All rights reserved